Press Releases Choose Year All Items 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 Search Press Releases Found 211 Results October 21, 2025 Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Preparation for US Commercial Launch, if Approved August 14, 2025 Minerva Neurosciences Provides Business Updates and Second Quarter Financial Results May 13, 2025 Minerva Neurosciences Reports First Quarter 2025 Financial Results and Business Updates February 25, 2025 Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Business Updates November 5, 2024 Minerva Neurosciences Reports Third Quarter 2024 Financial Results and Business Updates August 6, 2024 Minerva Neurosciences Reports Second Quarter 2024 Financial Results and Business Updates May 1, 2024 Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates February 27, 2024 Minerva Neurosciences Receives Complete Response Letter from FDA for New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia February 22, 2024 Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business Updates November 7, 2023 Minerva Neurosciences Reports 2023 Third Quarter Financial Results and Business Updates «12345...1020...»